Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehmet Altan

Showing results (61-70 of 153) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerKurt A Schalper, Daniel Carvajal-Hausdorf, Joseph McLaughlin, et al.
Annals of Gastroenterology|September 5, 2022
Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitorsKavea Panneerselvam, David Szafron, Rajan N Amin, et al.
NPJ Precision Oncology|June 12, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitorsHarold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, et al.
Journal for Immunotherapy of Cancer|April 4, 2019
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitisHamzah Abu-Sbeih, Faisal S Ali, Xuemei Wang, et al.
Journal of Cancer Research and Clinical Oncology|April 8, 2023
Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicityMalek Shatila, Weijie Ma, Yantong Cui, et al.
Clinical Lung Cancer|January 3, 2025
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic CarcinomaJennifer A Marks, Jaeil Ahn, Joshua E Reuss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
NPJ Breast Cancer|December 20, 2018
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancerMehmet Altan, Kelley M Kidwell, Vasiliki Pelekanou, et al.
Journal of Immunotherapy and Precision Oncology|May 22, 2023
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the LiteratureFelipe Soto, Luis F Torre-Sada, Frank E Mott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 8, 2021
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related EsophagitisKavea Panneerselvam, Rajan N Amin, Dongguang Wei, et al.
Pageof 16

Showing results (61-70 of 153) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerKurt A Schalper, Daniel Carvajal-Hausdorf, Joseph McLaughlin, et al.
Annals of Gastroenterology|September 5, 2022
Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitorsKavea Panneerselvam, David Szafron, Rajan N Amin, et al.
NPJ Precision Oncology|June 12, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitorsHarold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, et al.
Journal for Immunotherapy of Cancer|April 4, 2019
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitisHamzah Abu-Sbeih, Faisal S Ali, Xuemei Wang, et al.
Journal of Cancer Research and Clinical Oncology|April 8, 2023
Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicityMalek Shatila, Weijie Ma, Yantong Cui, et al.
Clinical Lung Cancer|January 3, 2025
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic CarcinomaJennifer A Marks, Jaeil Ahn, Joshua E Reuss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
NPJ Breast Cancer|December 20, 2018
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancerMehmet Altan, Kelley M Kidwell, Vasiliki Pelekanou, et al.
Journal of Immunotherapy and Precision Oncology|May 22, 2023
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the LiteratureFelipe Soto, Luis F Torre-Sada, Frank E Mott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 8, 2021
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related EsophagitisKavea Panneerselvam, Rajan N Amin, Dongguang Wei, et al.
Pageof 16